41 results about "CD8A" patented technology

The invention provides a BCMA-based (B cell maturation antigen-based) chimeric antigen receptor, comprising following cis-form cascade domains: CD8a leader region, scFv fragment BCMA scFv of anti-BCMA antibody, CD8a hinge region and transmembrane region, CD28 intracellular signal domain and CD3 Zeta intracellular signal domain; the CD3 Zeta intracellular signal domain is wild CD3 Zetaintracellular signal domain or mutant CD3 Zeta mut intracellular signal domain; the BCMA-based chimeric antigen receptor can enhance anti-apoptotic capability of T-cells and enhance CAR T-cell and antigen bonding and signal conduction; T-cells with the BCMA-based chimeric antigen receptor show good tumor targeting performance in in-vivo experiments, tumors diminish significantly after two weeks of dosage, and the T-cells have excellent therapeutic effect in vivo.

The invention relates to the technical field of medical diagnosis, and specifically relates to an X-linked lymphoproliferative syndrome diagnostic kit and application thereof. The kit comprises anti-human CD 3, CD56, CD8a and SAP flow fluorescent antibodies, an isotype control fluorescent antibody of the anti-human SAP flow fluorescent antibody, an anti-human SAP Western Blot antibody, and a secondary antibody corresponding to the anti-human SAP Western Blot antibody. A method for detecting SAP protein abundance in CTL and NK cells based on the diagnostic kit is quick to detect, high in flux, high in accuracy, and small in human factor influence.

The invention belongs to the field of tumor biological products, and discloses a chimeric antigen receptor and a gene thereof and a recombinant expression vector of the gene as well as a CAR133-NKT cell and a preparation method and application of the CAR133-NKT cell. The chimeric antigen receptor is CD133ScFv-CD8-CD137-CD3 zeta including tandem a CD8a signal peptide, a CD133ScFv, CD8 hinge and transmembrane regions, a CD137 intracellular signal domain and a CD3 zeta intracellular signal domain. The CAR133-NKT cell provided by the invention has very good specific killing activity against a CD133-positive epithelial tumor cell when co-culture is performed with the CD133-positive epithelial tumor cell; and the CAR133-NKT cell provided by the invention has a certain therapeutic effect on an epithelial tumor when treating the CD133-positive epithelial tumor.

The present invention provides a method for predicting the treatment response to anti-cancer immunotherapy of a mammalian cancer patient, the method comprising: a) measuring the gene expression of at least 2 the following cancer promoting genes: PTGS2, VEGFA, CCL2, IL8, CXCL2, CXCL1, CSF3, IL6, IL1B and IL A in a sample obtained from the tumour of the patient; b) measuring the gene expression of at least 2 of the following cancer inhibitory genes: CXCL11, CXCL10, CXCL9, CCL5, TBX21, EOMES, CD8B, CD8A, PRF1, GZMB, GZMA, STAT1, IFNG, IL12B and IL12A in a sample obtained from the tumour of the patient; c) computing a ratio of the gene expression of said at least 2 cancer promoting genes and the gene expression of said at least 2 cancer inhibitory genes; and d) making a prediction of the treatment response and/or prognosis of the patient based on the gene expression ratio computed in step c). Also provided are related methods for stratifying patients and for treating patients, including with immune checkpoint blockade therapy.

The invention belongs to the technical field of tumor immunotherapy, and particularly relates to a CXCL9 modified chimeric antigen receptor T (CAR-T) structure and application patent application matter thereof. The CXCL9 modified CAR-T structure meso-CAR-CXCL9 has a specific structure: CD8a-meso-CD28-CD3Zeta-P2A-CXCL9. In the application, inventors obtain CAR-T-CXCL9 cells based on mesothelin design by taking a lung cancer model as an example. Preliminary experiment results show that, compared with conventional CAR-T cells, the modified cells have higher cytokine secretion and cytotoxicity capacities, can obviously increase immune cell infiltration of a tumor site, and inhibit angiogenesis, and further, the modified CAR-T-CXCL9 cell therapy slows down tumor growth, increases the survival rate of mice, and shows excellent anti-tumor activity.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).

The invention discloses an immunoglobulin A nephropathy T cell diagnostic marker. On the first aspect, the invention provides application of a reagent for quantitatively detecting at least one of the following markers in preparation of the diagnostic kit for IgA nephropathy: CCR3, CD4, CD8A, GATA3, GZMA, HDAC7, RORA and VEGFC. According to the application disclosed by the embodiment of the invention, the application at least has the following beneficial effects that the pathogenesis of the immunoglobulin A nephropathy is related to five gene axes (Axis), screening is carried out from related mRNA gene expression data based on a specific gene or protein of a T cell from the T cell immune axis (T Cell Immunity Axis) to obtain the eight markers, and the immunoglobulin A nephropathy can be used for detecting the immunoglobulin A nephropathy. Whether a subject suffers from IgA nephropathy or not can be efficiently and accurately diagnosed through quantitative detection on the basis of at least one of the eight markers, and good specificity and sensitivity are achieved.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.

The invention relates to a method for preparing CAR-T (chimeric antigen receptor T) cells, which comprises the following steps of: synthesizing plasmids which are composed of a CD19 single-chain variable region, a CD8a hinge region, a CD8a transmembrane region, a 4-1BB signal, a CD3 zeta inclusion signal, an IL-7 sequence and a CCL17 sequence; packaging the virus to obtain a lentivirus concentrated solution, and measuring the virus titer of the lentivirus concentrated solution; and preparing T cells, namely activating, transducing and amplifying the prepared T cells which are CD8 < + > T cells, and harvesting CAR-T cells. The invention also relates to a method for preparing the T cell. The invention has excellent effects as described in the specification.

The invention relates to a trophoblast, a preparation method thereof and application of the trophoblast in massive rapid amplification of gamma delta T cells. The preparation method comprises the following steps: S1, constructing a pLenti-okt3-CD64-CD86-4.1BBL lentiviral plasmid vector; S2, packaging lentiviral particles by using the pLenti-okt3-CD64-CD86-4.1BBL plasmid vector; S3, preparing K562-okt3-CD64-CD86-4.1BBL trophoblast; S4, obtaining buffy coat cells of umbilical cord blood; and S5, carrying out in vitro amplification on gamma delta T cells of the umbilical cord blood. According tothe preparation method, an okt3 single-chain antibody is expressed on a trophoblast membrane through a CD8A transmembrane region, especially, the gamma delta T cells can be rapidly and massively amplified from the umbilical cord blood at low cost, the amplification multiple of the gamma delta T cells can reach about 10000 times after a 24-day amplification period, and the purity of the prepared gamma delta T cells can reach 90% or above. Compared with stimulation by a soluble okt3 antibody, the membrane-bound okt3 has the amplification multiple over 2 times to the gamma delta T cells, and hasa good clinical application prospect.

The invention provides a kit for simultaneously detecting various cell subpopulations and functional changes and application of the kit. The kit comprises an antibody composition, and the antibody composition comprises a surface antibody composition and an intracellular antibody composition. The surface antibody composition comprises a combination of at least two of Zombie NIR, CD45, Ly6G, CD11b, F4/80, Ly6c, NK1.1, CD3, CD4, CD25, CD8a, CD19, CD11c, CD80 and CD206. The intracellular antibody composition comprises a combination of at least two of FoxP3, IL-10, Granzyme B, Perforin and IFNgamma. The invention also provides a method for detecting the change of the immune cell subpopulations. The kit can be used for simultaneously detecting changes of a plurality of immune cell subgroups and functions, and the result is comprehensive and specific.